01—Abstract
Summary
Summary of the 10-Q filed May 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories reported Q1 2024 results with a modest 2.2% increase in net sales to $9.964 billiona, driven by growth in Medical Devices and Established Pharmaceuticals, partially offset by a significant decline in Diagnostic Products sales.
Excluding foreign exchange impacts, net sales rose 5.1%, with a notable 11.3% increase when also excluding COVID-19 testing revenue. The company's earnings before taxes stood at $1.436 billionb, with Net Earnings of $1.225 billion, translating to diluted Earnings Per Share (EPS) of $0.70, a decrease from $0.75 in the prior year period. The Medical Devices segment showed strong performance, particularly in Diabetes Care (FreeStyle Libre sales up 23.3% ex-FX) and Electrophysiology, while Established Pharmaceuticals saw growth in key emerging markets.
However, Diagnostic Products experienced a sharp 17.6%c decline (15.5% ex-FX), primarily due to a substantial drop in COVID-19 testing sales. Operationally, gross profit margin remained stable at 50.5%, indicating effective cost management despite ongoing R&D and SG&A investments to support growth. The company continues to manage its debt prudently, with total long-term debt decreasing and maintaining strong credit ratings.
Abbott also returned capital to shareholders through dividends and share repurchases. While the company faces ongoing legal and tax matters, management remains confident in their impact on the financial position. The significant decrease in COVID-19 testing revenue continues to be a headwind, but the underlying performance in key growth segments like Medical Devices provides a positive outlook.
02—Key points
Key Highlights
- Net sales increased by 2.2% to $9.964 billion for Q1 2024, with a 5.1% increase on an organic (ex-FX) basis.
- Net earnings decreased to $1.225 billion ($0.70 EPS) from $1.318 billion ($0.75 EPS) in Q1 2023, reflecting a challenging comparison period.
- Medical Devices segment revenue grew 14.2% (15.4% ex-FX), driven by strong performance in Diabetes Care and Electrophysiology.
- Diagnostic Products sales declined 17.6% (15.5% ex-FX), significantly impacted by an 72% drop in COVID-19 testing sales year-over-year.
- FreeStyle Libre sales reached $1.5 billion, up 23.3% ex-FX, highlighting strong momentum in the Diabetes Care business.
- The company generated $1.025 billion in net cash from operating activities, a slight decrease from $1.143 billion in the prior year, reflecting lower operating earnings and increased trade receivables.
- Abbott continues to return capital to shareholders, with a quarterly dividend of $0.55 per share, an increase of 7.8% from the prior year.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Abbott Laboratories kept $0.12.
- Revenue$9.96B100.0%
- Cost of revenue−$4.46B44.8%
- Gross profit$5.50B55.2%
- Operating costs−$4.12B41.3%
- Operating income$1.39B13.9%
- Interest, other & tax−$161.0M1.6%
- Net income$1.23B12.3%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 2, 2024Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $9.96B$9.75B | +2.2% |
| Cost of Revenue | $4.46B$4.33B | +3.0% |
| Gross Profit | $5.50B$5.42B | +1.6% |
| R&D Expenses | $684.00M$654.00M | +4.6% |
| SG&A Expenses | $2.96B$2.76B | +7.1% |
| Operating Expenses | $8.58B$8.24B | +4.1% |
| Operating Income | $1.39B$1.51B | −8.2% |
| Interest Expense | $141.00M$153.00M | −7.8% |
| Net Income | $1.23B$1.32B | −7.1% |
| EPS (Basic) | $0.70$0.75 | −6.7% |
| EPS (Diluted) | $0.70$0.75 | −6.7% |
| Shares Outstanding (Basic) | 1.74B1.74B | −0.1% |
| Shares Outstanding (Diluted) | 1.75B1.75B | −0.1% |
05—Questions
Frequently Asked Questions
What was the primary driver behind the significant decrease in Diagnostic Products revenue?
The substantial decrease in Diagnostic Products revenue, down 17.6% year-over-year (15.5% excluding foreign exchange), was primarily driven by the significant decline in demand for COVID-19 testing products. COVID-19 testing-related sales in this segment dropped from $730 million in Q1 2023 to $204 million in Q1 2024.
How is Abbott managing its debt and what is its liquidity position?
Abbott maintains a strong liquidity position with $6.284 billion in cash and cash equivalents as of March 31, 2024. The company also has access to $5 billion through an unused line of credit. Long-term debt has decreased, and Abbott holds investment-grade credit ratings (AA- from S&P, Aa3 from Moody's), indicating a stable financial footing.
What is the outlook for the Medical Devices segment, and which products are performing well?
The Medical Devices segment showed robust growth, with revenue increasing by 14.2% (15.4% excluding foreign exchange). Key performers include the FreeStyle Libre continuous glucose monitoring system, which saw a 23.3% increase in sales (ex-FX) to $1.5 billion, and double-digit growth in areas like Electrophysiology, Vascular, Structural Heart, and Neuromodulation. This segment is a significant growth engine for Abbott.
Are there any significant legal or tax matters that investors should be aware of?
Abbott is involved in various legal proceedings and tax examinations. Notably, the company is contesting a $417 million IRS notice of deficiency for its 2019 Federal tax year related to income reallocation. While Abbott believes its positions are valid, there is a possibility of unfavorable outcomes or cash adjustments in tax matters. The company also noted a patent infringement trial against DexCom where the jury found infringement, with damages to be determined later. Management believes the ultimate disposition of these matters will not have a material adverse effect on the company's financial position.
06—Continue